Clinical Trials Logo

Recurrent Childhood Central Nervous System Embryonal Tumor clinical trials

View clinical trials related to Recurrent Childhood Central Nervous System Embryonal Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT01088763 Terminated - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Start date: March 2010
Phase: Phase 1
Study type: Interventional

This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemia. Gamma-secretase inhibitor RO4929097 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01076530 Completed - Clinical trials for Recurrent Childhood Medulloblastoma

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Start date: February 2010
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug.

NCT ID: NCT00994500 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

Start date: August 2009
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating young patients with refractory or recurrent solid tumors, including CNS tumors and lymphoma. Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00929903 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment

Start date: June 2009
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of pazopanib hydrochloride in treating young patients with solid tumors that have relapsed or not responded to treatment. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00387920 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Sunitinib in Treating Young Patients With Refractory Solid Tumors

Start date: October 2006
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of sunitinib in treating young patients with refractory solid tumors. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor.

NCT ID: NCT00281944 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors

Start date: September 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of oxaliplatin when given together with leucovorin and fluorouracil in treating young patients with advanced solid tumors. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.